Skip to content

A multi-center RCT study on the clinical efficacy of Tongliyanqiao combined with rTMS in the treatment of dysphagia after ischemic stroke

A multi-center RCT study on the clinical efficacy of Tongliyanqiao combined with rTMS in the treatment of dysphagia after ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085518
Enrollment
Unknown
Registered
2024-06-11
Start date
2024-06-11
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia after ischemic stroke

Interventions

Treatment group:Tongliyanqiao acupuncture combined with rTMS
Control group 1:Tongliyanqiao acupuncture

Sponsors

The First Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Patients diagnosed by CT or MRI, who meet the above diagnostic criteria of Chinese and Western medicine, and the staging criteria belong to the convalescent stage; ?Age 40-80 years old, gender is not limited; ?WST=2, and VFSS confirmed the presence of pharyngeal dysphagia; ?VFSS score, oral stage 2 to 3 points; ? Stable condition (no progress in symptoms and signs within 48h, stable vital signs), clear consciousness, able to understand basic instructions, no serious cognitive dysfunction, can cooperate with treatment; ? no sequelae such as dysphagia were left after the onset of the disease for the first time or a history of previous stroke, and acupuncture, rehabilitation and other related treatments were not used recently; ? Volunteers to participate in the clinical trial study and cooperate with the examination and treatment, and sign the informed consent. Those who meet the above criteria can be included.

Exclusion criteria

Exclusion criteria: ? Those who do not meet the above diagnostic criteria or inclusion criteria; ?Patients with severe primary diseases such as heart, lung, liver, kidney, rheumatism, immune, endocrine, or heart, lung, liver, kidney, or brain failure; ? Patients with swallowing disorders not caused by the above cerebrovascular accidents; ?Patients with complete aphasia, true bulbar palsy, or speech dysfunction can not cooperate with the scale examination; ? Allergic to contrast agents; ? Women who are pregnant or breastfeeding; ? People with other medical conditions who are using drugs or are receiving treatment that may have an impact on this study indicator; ?Patients who suffer from needle faintness or sustained skin tissue damage, infection, coagulation dysfunction and skin allergy at the acupuncture site; ? Patients have no desire for treatment and are unwilling to cooperate; Patients who refuse to participate in experimental studies; Those meeting any of the above criteria are excluded.

Design outcomes

Primary

MeasureTime frame
Standardized swallowing assessment;

Secondary

MeasureTime frame
VFSS;Fiberoptic endoscopic evaluation of swallowing;SWAL-QOL;Barthel index;

Countries

China

Contacts

Public ContactLi zhengyu

The First Hospital of Hunan University of Chinese Medicine

616156000@qq.com+86 187 1150 2056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026